Inpatient Single Dose Interventions for Alcohol Use Disorder

Randomised, parallel-group pilot assessing single-dose XR naltrexone (380 mg IM) or IV ketamine (0.5 mg/kg over 40 minutes) versus enhanced linkage alone among hospitalised patients with severe AUD to evaluate feasibility and 30-day readmission.

Feasibility outcomes include recruitment rate, patient acceptability, post-discharge follow-up rate, and adverse events; the study will estimate 30-day re-admission rates to inform a future comparative effectiveness trial.